Erlotinib and RAD001 (Everolimus) in Patients With Previously Treated Advanced Pancreatic Cancer

• Sponsor: M.D. Anderson Cancer Center (Other)
• Overall Status: Terminated
• CT.gov ID: NCT00640978
• Collaborator: Novartis (Industry), OSI Pharmaceuticals (Industry)
• Enrollment: 16
• Location: 1
• Arm: 1
• Duration (Months): 24
• Patients Per Site Per Month: 0.7

Study Details

Study Description

Brief Summary

The goal of this clinical research study is to learn if the combination of RAD001 and erlotinib hydrochloride can slow the growth of advanced pancreatic cancer. The safety of this drug combination will also be studied.

Primary Objectives:

-Determine the overall survival (OS) at 6 months of the combination of erlotinib and RAD001 in patients who have received previous treatment for advanced pancreatic cancer.

Secondary Objectives:

• Determine the progression-free survival (PFS).

• Determine the response rate (RR).

Condition or Disease	Intervention/Treatment	Phase
Pancreatic Cancer	Drug: RAD001; Drug: Erlotinib	Phase 2

Detailed Description

The Study Drugs:

RAD001 is designed to stop cancer cells from multiplying. It may also stop the growth of new blood vessels that help tumor growth, which may cause the tumor cells to die.

Erlotinib hydrochloride is designed to block the activity of a protein found on the surface of many tumor cells that may control tumor growth and survival. This may stop tumors from growing.

Study Drug Administration:

If you are found to be eligible to take part in this study, you will take erlotinib hydrochloride by mouth every day of each 28-day study "cycle". You should take erlotinib hydrochloride once a day in the morning with 1 cup (about 8 oz.) of water. Erlotinib hydrochloride should be taken at least 1 hour before or 2 hours after you have any food, vitamins, iron supplements, or other non-prescription drugs.

On Days 1, 8, 15, and 22 of each cycle, you will take RAD001 by mouth in the morning. You should either take the study drug on an empty stomach with 2 cups (about 16 oz.) of water or after a low-fat meal. You should not take the study drug after large fatty meals because fatty meals lower the amount of the study drug in your body. Some examples of a low-fat meal include cereal with fat-free milk, a low-fat muffin, toast, or a bagel with fat-free spread, or fruit salad.

On days when you take both RAD001 and erlotinib hydrochloride, RAD001 should be taken right before erlotinib hydrochloride.

If you experience intolerable side effects, you must call your doctor right away. The doctor may tell you to stop taking the study drugs or to take fewer pills. The study drugs may also be stopped completely, if your doctor thinks it is necessary.

Study Visits:

On Day 1 of every cycle, the following tests and procedures will be performed:

• You will have a physical exam, including measurement of your vital signs and weight.

• You will have a performance status evaluation.

• Blood (about 2 tablespoons) and urine will for collected for routine tests. You should be fasting at the time of the blood draw. You should not eat or drink anything except water after midnight the night before.

• You will be asked about any drugs you may be taking or have taken since your last visit.

On Day 8 of Cycle 1, the following tests and procedures will be performed:

• You will have a physical exam, including measurement of your vital signs and weight.

• Blood (about 2 tablespoons) and urine will be collected for routine tests. You should be fasting at the time of the blood draw. You should not eat or drink anything except water after midnight the night before.

• You will be asked about any drugs you may be taking or have taken since your last visit.

At the end of every even cycle (Cycles 2, 4, 6, and so on), you will have a CT or MRI scan to check the status of the disease. The scans will be the same type that you had during screening.

Length of Study:

You may remain on study as long as you are benefitting. You will be taken off study early if the disease gets worse, you have intolerable side effects, or if your doctor decides that it is in your best interest to stop treatment.

End-of-Study Visit:

About 14 days after the last dose of study drug, you will have an end-of-study visit. The following tests and procedures will be performed:

• You will have a physical exam, including measurement of your vital signs and weight.

• You will have a performance status evaluation.

• Blood (about 2-3 tablespoons) and urine will be collected for routine tests. You should be fasting at the time of the blood draw. You should not eat or drink anything except water after midnight the night before.

• If you have not had them within the last 4 weeks, you will have a CT or MRI scan to check the status of the disease. The scans will be the same type that you had during screening.

Long-Term Follow-Up:

After you go off study, you will be asked how you are doing once a month for the first 6 months from the beginning of the study treatment. Then you will be asked how you are doing every 3 months from then on. This may be done either by phone contact or a clinic visit and will take about 15-30 minutes.

This is an investigational study. Erlotinib hydrochloride in combination with gemcitabine is commercially available and FDA approved for the treatment of pancreatic cancer. RAD001 is not FDA approved or commercially available. At this time, the combination of these drugs is only being used in research.

Up to 40 patients will take part in this study. All will be enrolled at M. D. Anderson.

Study Design

• Study Type: Interventional
• Actual Enrollment: 16 participants
• Allocation: N/A
• Intervention Model: Single Group Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: Phase II Study of Erlotinib and RAD001 (Everolimus) in Patients With Previously Treated Advanced Pancreatic Cancer
• Study Start Date: Mar 1, 2008
• Actual Primary Completion Date: Mar 1, 2010
• Actual Study Completion Date: Mar 1, 2010

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Erlotinib + RAD001 Erlotinib 150 mg orally daily for 28 Days + RAD001 (Everolimus) 30 mg orally weekly for 4 Weeks	Drug: RAD001; 30 mg orally weekly for 4 weeks; Other Names: Everolimus ; Drug: Erlotinib; 150 mg by mouth daily for 28 Days; Other Names: Erlotinib Hydrochloride OSI-774 Tarceva

Outcome Measures

Primary Outcome Measures

1. Number of Participants Surviving at 6 Months [6 months]

   Overall survival (OS) at 6 months in participants receiving a combination of Erlotinib and RAD001 who have received previous treatment for advanced pancreatic cancer. OS at 6 months is number of participants alive at 6 months.

Eligibility Criteria

Criteria

• Ages Eligible for Study: 18 Years and Older
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Inclusion Criteria:

• Patients must have histologically or cytologically confirmed advanced pancreatic adenocarcinoma that is unresectable or metastatic.

• Patients must have received at least one prior chemotherapy regimen for unresectable/ metastatic disease. There is no limit to number of prior regimens. Prior erlotinib therapy is allowed.

• Minimum of two weeks since any major surgery, completion of radiation, or completion of all prior systemic anticancer therapy. Patients must have recovered from the acute toxicities of any prior therapy to NIH-NCI Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0 </= Grade 1.

• Age >/= 18 years. Because no dosing or adverse event data are currently available on the use of erlotinib administered in combination with RAD001 in patients < 18 years of age, children are excluded from this study.

• Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.

• Patients must have at least one measurable site of disease according to Response Evaluation Criteria In Solid Tumors (RECIST). This site must be outside a radiation field.

• Adequate hematologic, hepatic and renal parameters: leukocytes =/>3,000/ul, absolute neutrophil count =/>1,500/ul, platelets =/>100,000/ul, hemoglobin =/>9g/dL, total bilirubin </= 1.5 mg/dl, aspartate aminotransferase (AST) </=230 and alanine aminotransferase (ALT) </=280 IU/L for subjects with documented liver metastases; AST </=115 and ALT </=140 IU/L for subjects without evidence of liver metastases, creatinine </=1.5 mg/dl in males, </= 1.2 mg/dl in females.

• Women of childbearing potential (WOCBP) and men must agree to use adequate contraception prior to study entry for the duration of study treatment and 30 days after the end of treatment. WOCBP is defined as a woman who has not been naturally postmenopausal for at least 12 consecutive months or no previous surgical sterilization. Oral, implantable, or injectable contraceptives may be affected by cytochrome P450 interactions and are therefore not considered effective for this study. WOCBP must provide a negative pregnancy test (serum or urine) within 7 days prior to treatment.

• (Continuation of # 8) Acceptable contraception includes double-barrier methods (any double combination of: male or female condom with spermicidal gel, diaphragm, sponge, cervical cap, IUD).

• Signed written informed consent document. Written informed consent must be obtained prior to any evaluations being performed solely for the purposes of screening for eligibility for this study.

Exclusion Criteria:

• Prior treatment with any investigational drug within the preceding 2 weeks

• Chronic treatment with systemic steroids or another immunosuppressive agent. Patients can not receive immunization with attenuated live vaccines within one week of study entry or during study period

• Limits for fasting lipids must be: cholesterol </= 300mg/dL and triglyceride </= 2.5 times upper limits of normal (ULN). Patients may be allowed to enroll on the trial after initiation of lipid lowering agents

• Uncontrolled brain or leptomeningeal metastases, including patients who continue to require glucocorticoids for brain or leptomeningeal metastases (Brain imaging studies are not required if the patient does not have a history of brain metastases and has no neurological signs or symptoms)

• Other malignancies within the past 3 years except for adequately treated carcinoma of the cervix or basal or squamous cell carcinomas of the skin

• Patients who have any severe and/or uncontrolled medical conditions or other conditions that could affect their participation in the study such as: unstable angina pectoris, symptomatic congestive heart failure, myocardial infarction </= 6 months prior to first study treatment, serious uncontrolled cardiac arrhythmia; severely impaired lung function (oxygen dependent, Common Terminology Criteria (CTC) Grade 3 or 4 dyspnea); uncontrolled diabetes as defined by fasting serum glucose >1.5 times ULN; any active (acute or chronic) or uncontrolled infection / disorders

• Patients who have any severe and/or uncontrolled medical conditions or other conditions that could affect their participation in the study such as: nonmalignant medical illnesses that are uncontrolled or whose control may be jeopardized by the treatment with the study therapy ; liver disease such as cirrhosis, known chronic active hepatitis or chronic persistent hepatitis; A known history of HIV seropositivity

• Patients who have any severe and/or uncontrolled medical conditions or other conditions that could affect their participation in the study such as: Impairment of gastrointestinal function or gastrointestinal disease that may significantly alter the absorption of RAD001 and/or erlotinib (e.g., ulcerative disease, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome or small bowel resection)

• Patients with an active, bleeding diathesis (if coumarin is used, weekly monitoring is recommended)

• Women who are pregnant or breast feeding, or women/men able to conceive and unwilling to practice an effective method of birth control. (Women of childbearing potential must have a negative urine or serum pregnancy test within 7 days prior to administration of RAD001). Oral, implantable, or injectable contraceptives may be affected by cytochrome P450 interactions, and are therefore not considered effective for this study. Acceptable contraception includes double-barrier methods (any double combination of: male or female condom with spermicidal gel, diaphragm, sponge, cervical cap, intrauterine device [IUD]).

• Patients who have received prior treatment with an mTor inhibitor

• Patients with a known hypersensitivity to erlotinib, RAD001 (everolimus) or other rapamycins (sirolimus, temsirolimus) or to its excipients

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	U.T.M.D. Anderson Cancer Center	Houston	Texas	United States	77030

Sponsors and Collaborators

• M.D. Anderson Cancer Center
• Novartis
• OSI Pharmaceuticals

Investigators

• Principal Investigator: Milind Javle, MD, M.D. Anderson Cancer Center

Study Documents (Full-Text)

None provided.

More Information

Additional Information:

• UT MD Anderson Cancer Center

Publications

None provided.

• Responsible Party: M.D. Anderson Cancer Center
• ClinicalTrials.gov Identifier: NCT00640978
• Other Study ID Numbers: 2007-0666
• First Posted: Mar 21, 2008
• Last Update Posted: Jun 25, 2012
• Last Verified: Jun 1, 2012

• Keywords provided by M.D. Anderson Cancer Center: Pancreatic Cancer; Advanced Pancreatic Cancer; Unresectable; Metastatic; RAD001; Everolimus; Erlotinib; OSI-774; Erlotinib Hydrochloride; Tarceva
• Additional relevant MeSH terms: Pancreatic Neoplasms; Everolimus; Erlotinib Hydrochloride

Study Results

Participant Flow

Recruitment Details	Recruitment Period: March 2008 through January 20, 2009. All recruitment done at UT MD Anderson Cancer Center.
Pre-assignment Detail	Of the sixteen registered, one (1) participant was enrolled but did not receive the planned treatment.

Arm/Group Title	Erlotinib + RAD001
Arm/Group Description	Erlotinib 150 mg orally daily for 28 Days + RAD001 (Everolimus) 30 mg orally weekly for 4 Weeks
Period Title: Overall Study
STARTED	15
COMPLETED	15
NOT COMPLETED	0

Baseline Characteristics

Arm/Group Title	Erlotinib + RAD001
Arm/Group Description	Erlotinib 150 mg orally daily for 28 Days + RAD001 (Everolimus) 30 mg orally weekly for 4 Weeks
Overall Participants	15
Age (years) [Mean (Full Range) ]
Mean (Full Range) [years]	63
Sex: Female, Male (Count of Participants)
Female	4 26.7%
Male	11 73.3%
Region of Enrollment (participants) [Number]
United States	15 100%

Outcome Measures

1. Primary Outcome

Title	Number of Participants Surviving at 6 Months
Description	Overall survival (OS) at 6 months in participants receiving a combination of Erlotinib and RAD001 who have received previous treatment for advanced pancreatic cancer. OS at 6 months is number of participants alive at 6 months.
Time Frame	6 months

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Erlotinib + RAD001
Arm/Group Description	Erlotinib 150 mg orally daily for 28 Days + RAD001 (Everolimus) 30 mg orally weekly for 4 Weeks
Measure Participants	15
Number [Participants]	15 100%

Adverse Events

Time Frame	Adverse events data were collected from March 07, 2008 to August 12, 2008 or a total of 6 months.
Arm/Group Title	Erlotinib + RAD001
Arm/Group Description	Erlotinib 150 mg orally daily for 28 Days + RAD001 (Everolimus) 30 mg orally weekly for 4 Weeks
All Cause Mortality
	Erlotinib + RAD001
	Affected / at Risk (%)	# Events
Total	/ (NaN)
Serious Adverse Events
	Erlotinib + RAD001
	Affected / at Risk (%)	# Events
Total	0/16 (0%)
Other (Not Including Serious) Adverse Events
	Erlotinib + RAD001
	Affected / at Risk (%)	# Events
Total	16/16 (100%)
Blood and lymphatic system disorders
Anemia	1/16 (6.3%)
Hemoglobin	1/16 (6.3%)
Leukocytes	1/16 (6.3%)
Lymphopenia	5/16 (31.3%)
Eye disorders
Dry eyes	1/16 (6.3%)
Gastrointestinal disorders
Abdominal Pain	5/16 (31.3%)
Anorexia	6/16 (37.5%)
Dehydration	3/16 (18.8%)
Diarrhea	9/16 (56.3%)
Distention/bloating	1/16 (6.3%)
Gastrointestinal obstruction	1/16 (6.3%)
Mucositis (oral)	2/16 (12.5%)
Nausea	5/16 (31.3%)
Stomatitis	1/16 (6.3%)
Taste Alteration	1/16 (6.3%)
Vomiting	3/16 (18.8%)
General disorders
Confusion	1/16 (6.3%)
Dehyration	1/16 (6.3%)
Dizziness	1/16 (6.3%)
Fatigue	6/16 (37.5%)
Fever without neutropenia	4/16 (25%)
Mood Alteration (Anxiety)	2/16 (12.5%)
Rigor/chills	1/16 (6.3%)
Xerostoma	1/16 (6.3%)
Infections and infestations
Infection with normal neutrophils	2/16 (12.5%)
Investigations
Weight Loss	5/16 (31.3%)
Metabolism and nutrition disorders
Alkaline Phosphatase	5/16 (31.3%)
Bilirubin	1/16 (6.3%)
Cholesterol (serum high)	1/16 (6.3%)
Hyperglycemia	3/16 (18.8%)
Hyperkalemia	1/16 (6.3%)
Hypertriglyceridemia	4/16 (25%)
Hypoatremia	2/16 (12.5%)
Hypokalemia	1/16 (6.3%)
Serum glutamic oxaloacetic transaminase (AST, SGOT)	2/16 (12.5%)
Serum glutamic pyruvic transaminase (ALT)	2/16 (12.5%)
Musculoskeletal and connective tissue disorders
Muscle Weakness	3/16 (18.8%)
Pain (back)	2/16 (12.5%)
Pain(joint)	1/16 (6.3%)
Reproductive system and breast disorders
Erectile dysfunction	1/16 (6.3%)
Yeast infection	2/16 (12.5%)
Respiratory, thoracic and mediastinal disorders
Cough	1/16 (6.3%)
Skin and subcutaneous tissue disorders
Acne	7/16 (43.8%)
Dry Skin	3/16 (18.8%)
Rash (hand and foot eeaction)	1/16 (6.3%)
Rash/Desquamation	2/16 (12.5%)
Vascular disorders
Thrombosis	1/16 (6.3%)

Limitations/Caveats

[Not Specified]

More Information

Certain Agreements

All Principal Investigators ARE employed by the organization sponsoring the study.

There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.